Skip to content
10-Q

Quarterly Report

PharmaCyte Biotech, Inc. PMCB

0001683168-25-009259

← back to feed
Filed
Dec 18, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Dec 16, 2025 10.13M sh
Shares Diluted Q2 2026 · Oct 31, 2025 6.8M sh
Shares Diluted Q2 2026 · Oct 31, 2025 6.8M sh
Shares Diluted Q2 2026 · Oct 31, 2024 7.64M sh
Shares Diluted Q2 2026 · Oct 31, 2024 7.75M sh
Stock Repurchased Q2 2026 · Oct 31, 2025 $0
Stock Repurchased Q2 2026 · Oct 31, 2024 $2.15M
Operating Cash Flow Q2 2026 · Oct 31, 2025 −$2.97M
Operating Cash Flow Q2 2026 · Oct 31, 2024 −$1.43M
Cash And Equivalents Q2 2026 · Oct 31, 2025 $15.41M
Cash And Equivalents Q2 2026 · Apr 30, 2025 $15.17M
Stockholders Equity Q2 2026 · Oct 31, 2025 $35.24M
Stockholders Equity Q2 2026 · Jul 31, 2025 $43.59M
Stockholders Equity Q2 2026 · Apr 30, 2025 $51.89M
Stockholders Equity Q2 2026 · Oct 31, 2024 $43.45M
Stockholders Equity Q2 2026 · Jul 31, 2024 $47.71M
Stockholders Equity Q2 2026 · Apr 30, 2024 $27.65M
Current Liabilities Q2 2026 · Oct 31, 2025 $1.58M
Current Liabilities Q2 2026 · Apr 30, 2025 $2.91M
Total Liabilities Q2 2026 · Oct 31, 2025 $19.42M
Total Liabilities Q2 2026 · Apr 30, 2025 $3.28M
Current Assets Q2 2026 · Oct 31, 2025 $23.02M
Current Assets Q2 2026 · Apr 30, 2025 $22.38M
Total Assets Q2 2026 · Oct 31, 2025 $55.98M
Total Assets Q2 2026 · Apr 30, 2025 $55.17M
Eps Diluted Q2 2026 · Oct 31, 2025 −$1.24
Eps Diluted Q2 2026 · Oct 31, 2025 −$2.47
Eps Diluted Q2 2026 · Oct 31, 2024 −$0.39
Eps Diluted Q2 2026 · Oct 31, 2024 $1.83
Eps Basic Q2 2026 · Oct 31, 2025 −$1.24
Eps Basic Q2 2026 · Oct 31, 2025 −$2.47
Eps Basic Q2 2026 · Oct 31, 2024 −$0.39
Eps Basic Q2 2026 · Oct 31, 2024 $1.83
Rd Expense Q2 2026 · Oct 31, 2025 $141.09K
Rd Expense Q2 2026 · Oct 31, 2025 $236.24K
Rd Expense Q2 2026 · Oct 31, 2024 $97.47K
Rd Expense Q2 2026 · Oct 31, 2024 $193.49K
Net Income Q2 2026 · Oct 31, 2025 −$7.42M
Net Income Q2 2026 · Oct 31, 2025 −$15.78M
Net Income Q2 2026 · Jul 31, 2025 −$8.36M
Net Income Q2 2026 · Oct 31, 2024 −$1.47M
Net Income Q2 2026 · Oct 31, 2024 $21.95M
Net Income Q2 2026 · Jul 31, 2024 $23.42M
Operating Income Q2 2026 · Oct 31, 2025 −$1.38M
Operating Income Q2 2026 · Oct 31, 2025 −$2.22M
Operating Income Q2 2026 · Oct 31, 2024 −$1.11M
Operating Income Q2 2026 · Oct 31, 2024 −$2.37M
Revenue Q2 2026 · Oct 31, 2025 $0
Revenue Q2 2026 · Oct 31, 2025 $0
Revenue Q2 2026 · Oct 31, 2024 $0
Revenue Q2 2026 · Oct 31, 2024 $0